Erschienen in:
08.11.2019 | Letter to the Editor
Response to the letter to the Editor concerning our article “High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany”
verfasst von:
Stefan Feiten, Geothy Chakupurakal, Hans Peter Feustel, Michael Maasberg, Burkhard Otremba, Peter Ehscheidt, Manfred Hensel, Richard Hansen, Rudolf Weide
Erschienen in:
Supportive Care in Cancer
|
Ausgabe 1/2020
Einloggen, um Zugang zu erhalten
Excerpt
We appreciate the interest in our work and the letter to the editor of Cransac et al. [
1]. In our paper, we stated that myeloma patients who are treated with immunomodulatory drugs (IMIDS) in hematology/oncology group practices seem to be highly adherent [
2]. We measured adherence with the help of different methods and found concordant results and therefore believe that patients are highly adherent to IMIDS in reality. Reasons for high adherence in our oncology group practice setting are a constant patient-doctor-relationship and frequent consultations in which the adherence and tolerance of the medication is discussed between patient, doctor, and caregiver. We acknowledge that adherence is difficult to measure and that there is still no “gold standard” available [
3‐
7]. We agree that there are serious problems with each measuring method [
5] and that only a combination of measures can maximize accuracy [
8‐
10]. …
